ClinicalTrials.gg
RecruitingNCT05285124HD-tDCSUpdated Jun 4, 2024

HD-tDCS Combined With Circadian Rhythm Reconstruction and Micro Expression Changes on Consciousness Recovery in Patients With Chronic Disturbance of Consciousness

An interventional study of Melatonin and Placebo in Disorder of Consciousness, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Consciousness Disorders by First Affiliated Hospital of Zhejiang University — 4 open to participants now, 4 under way, none of them phase 3. Consciousness Disorders · First Affiliated Hospital of Zhejiang University.

Started
2021
with 1 other
No phase
7 of 17
1 open now
Registered
12th of 17
by date

Among the 17 studies in Consciousness Disorders by First Affiliated Hospital of Zhejiang University, this one is one of 2 that started in 2021, is one of 7 with no phase, and was the 12th registered.

Consciousness Disorders

291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.

Browse Consciousness Disorders studies →

Open to participants now

4 of the 17 studies in Consciousness Disorders by First Affiliated Hospital of Zhejiang University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Consciousness Disorders by First Affiliated Hospital of Zhejiang University, or all of them as a file.
02

Study summary

The circadian rhythm characteristics of sleep cycle and neuroendocrine in patients with chronic disorder of consciousness show different degrees of disorder, and the relationship between this disorder and consciousness level is unclear.The researchers used HD-tDCS to treat patients with chronic disturbance of consciousness who intervened in circadian rhythm, and used a variety of methods such as EEG, fMRI, protein metabolism, ERP and micro-expression to explore the mechanism of improving the state of consciousness of HD-DCS and the relationship between circadian rhythm and patients' consciousness level

Read the detailed description

The sleep status (> 24 hours) of patients with chronic disturbance of consciousness was recorded with the revised coma recovery scale revised (CRS-R) and Polysomnography (PSG). The sleep cycle of patients with chronic disturbance of consciousness was judged by the open and close eyes cycle and EEG.

Patients with circadian rhythm treated with or without blue light stimulation and melatonin were treated with HD-tDCS. EEG, fMRI, protein metabolism, ERP and micro expression data were recorded before and after treatment.Explore the mechanism of improving the state of consciousness of HD-DCS and the relationship between circadian rhythm and patients' consciousness level

03

Conditions studied

  • Disorder of Consciousness

Keywords

  • disorder of consciousness
  • Circadian rhythm
  • HD-tDCS
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with diagnosis of disorder of consciousness
  • Stable vital signs
  • Good coordination, less spontaneous activity
  • No anti-epileptic and sedative drugs taken within prior 24 hours
  • The family members volunteered and signed the

Exclusion criteria

Exclusion Criteria:

  • locked-in syndrome
  • Diseases and factors that may affect the judgment of brain function, such as metabolic diseases, poisoning, shock, etc.
  • There are to MRI scanning, such as the presence of metal implants in the body
  • Contraindications treated by transcranial direct current stimulation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    tDCS and melatonin intervention

    In real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes. Participants were given a 3-mg fast-release oral dose of melatonin.

    Drug: Melatonin · Other: HD-tDCS

  • Experimental
    tDCS intervention

    In real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.

    Other: Placebo · Other: HD-tDCS

  • Experimental
    Melatonin intervention

    Participants were given a 3-mg fast-release oral dose of melatonin.

    Drug: Melatonin

  • Placebo comparator
    Control

    Patients were treated with the placebo and sham-tDCS.

    Other: Placebo

Interventions

  • Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00

  • OtherPlacebo

    Participants in this group were treated according to a protocol identical to those receiving active medication at approximately 21:00. For the sham tDCS groups, the same stimulation parameters were employed, except that the stimulator had a built-in placebo mode; when it was activated, two ramp fade-in/fade-out periods in the beginning and the end of sham stimulation mimicked the somatosensory artifact of real tDCS

  • OtherHD-tDCS

    Direct current was applied using a battery-driven constant-current stimulator through saline-soaked surface sponge electrodes (7cm×5cm) with the anode placed over the left DLPFC (F3 according to the 10-20 international EEG system) and the reference cathode placed over the right supraorbital region (Fp2). During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes

06

What researchers measure

Primary outcomes

  1. The Coma Recovery Scale-Revised (CRS-R) scale

    The CRS-R is a tool used to characterise the level of consciousness consisting of 23 hierarchically arranged items that comprise six subscales addressing the auditory, visual, motor, oromotor/verbal, communication and arousal processes. The values range from 0 to 23, with higher score indicating better outcome.

    Time frame: Change from Baseline CRS-R at 14 days.

  2. Electroencephalography (EEG)

    Delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz) and beta (12-30 Hz). An increase of delta and theta activity usually reflects encephalopathy and/or structural lesions, interpreted as poor outcome predictor of DOC .The power of α and β is related to the chance of recovery.

    Time frame: Change from baseline EEG power spectral density at 14 days.

  3. Sleep parameters

    Changes in in sleep/wake architecture assessed by polysomnography. Electrodes attached to the scalp near the frontal, central (top) and occipital (back) portions of the brain and provide a readout of different stages of sleep (N1, N2, N3, REM, and Wakefulness).

    Time frame: Change from baseline sleep patterns at 14 days.

  4. Resting state fMRI

    Resting state fMRI reflects the brain activity occured in a resting or task-negative state. Regional (ReHo, ALFF, fALFF, etc.) and global parameters (functional connectivity, etc.) could be used in this study.

    Time frame: Change from ReHo, ALFF, fALFF and functional connectivity at 14 days.

  5. Micro-expression

    After listening to auditory stimulations, transient alterations may occur on the micro expression of the subjects. High-resolution video will be taken to capture each subject's facial micro-expressions while listening to the auditory materials.

    Time frame: At baseline.

Secondary outcomes

  1. protein metabolism

    Changes of protein content in peripheral blood

    Time frame: Change from Baseline protein metabolism at 14 days.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Dec 2022, 17 months.

Of 90 non-industry interventional studies with no phase under Consciousness Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 64. This study's 17 months is below that.

Counting every sponsor, half of 95 studies reached it within 19 months; a quarter within 8 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2021
First posted
Mar 17, 2022
StartActual
Jul 1, 2021
Primary completionActual
Dec 31, 2022
CompletionEst.
Dec 2024
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05285124
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Jul 1, 2021
Primary completion
Dec 31, 2022
Completion
Dec 2024 (estimated)
Last update
Jun 4, 2024

Study contacts

Benyan Luo, PhD
Contact
luobenyan@zju.edu.cn
13967166677
Fangping He, MS
Contact
hefangping@126.com
13819114225
Benyan Luo, PhD
study director · The First Affiliated Hospital, Zhejiang University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion